Company Overview and News

Can Analog Devices Drive Its Way Into Your Portfolio?

2018-08-23 seekingalpha
Technology is the future. Analog devices (ADI) understood that concept a long time ago. While beginning in 1965, its history is full of innovative concepts that are still useful today in many aspects of our tech-filled lives. After finalizing its acquisition of Linear Technology Corporation in 2017, ADI is now aggressively pursuing the semiconductor industry. The company’s success doesn’t rely solely on innovation.

Oppenheimer Stays Selective on Semiconductor Stocks Before Earnings

2018-07-11 247wallst
It’s been an outstanding run for technology, especially semiconductors. Given the important role the industry plays in our economy, it probably has legs. With that in mind, after a multiyear run, it’s smart for investors to be very selective when putting down their bets, especially in the chip arena.

Analog Devices, Inc. (ADI) CEO Vincent Roche on Q2 2018 Results - Earnings Call Transcript

2018-05-30 seekingalpha
Good morning, and welcome to the Analog Devices Second Quarter Fiscal Year 2018 Earnings Conference Call, which is being audio webcast via telephone and over the web.

RBC Stays With 3 Big Semiconductor Stocks Despite Recent Concerns

2018-05-02 247wallst
If there is any industry for which red flags are starting to fly above most Wall Street firms, it’s semiconductors, and with good reason. Semiconductor stocks have produced blistering results over the past few years, and experienced investors are well aware of the cyclical nature of that industry. Without using the dreaded “It’s different this time,” it should be noted that demand in many new areas has skyrocketed and is expected to remain.

SunTrust Stays Very Cautious on Semiconductors: Just 5 to Buy Now

2018-04-25 247wallst
All great cycles come to an end, or at the minimum, slow down to more normal growth, and in the case of the semiconductors, it has been the kind of run that few tech sectors have seen in years. While the future remains bright, it may not be the white-hot bright of the past five years that produced outsized gains for investors.

5 Semiconductor Stocks to Buy With Limited Exposure to Apple

2018-04-23 247wallst - 1
While Apple Inc. (NASDAQ: AAPL) is a dominant technology player, it also tends to have peaks and valleys in its various business lines, which can expose vendors to inconsistent orders and earnings. Plus, the company announced recently it is planning to use its own chips in Macintosh computers starting in 2020. So for technology investors looking to stay on what has been a very hot semiconductor ride, it may make sense to focus on companies with little or no exposure to Apple.

Top 10 Power Ranking Divvy Techs

2018-04-10 seekingalpha
With Facebook (FB) and Amazon (AMZN) getting hit from right left and center these days, investors pretty much keep their focus on the FAANG. When we think of tech stocks, we often imagine a bunch of geeks typing on their computer with 3 screens in front of them. We also imagine young, hip and fast-moving companies with great potential to bring triple digit returns in our portfolio.

5 Stocks to Buy as Capital Spending Poised to Jump in 2018

2018-03-20 247wallst
When economic conditions are unsure, and there is any sort of worry around, both companies and consumers are generally reluctant to spend money, and with good reason. Who wants to put their capital at risk if there is a potential for an economic downturn like a recession? That’s when excess cash goes into the bank for the proverbial rainy day.

Analog Devices Prices Senior Notes, Gets Moody's Baa1 Rating

2018-03-12 zacks
Leading semiconductor company Analog Devices Inc. (ADI - Free Report) recently announced an offering of senior unsecured notes aggregating $750 million. These notes have been issued in two tranches of different amounts with varying coupon rates and maturities.

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to LLTC / Linear Technology Corp. on message board site Silicon Investor.

Linear Technology Corporation Linear Technology Corporation Linear Technology Corporation ADI - Analog Devices vs. LLTC Linear Technology ADI - Analog Devices vs. LLTC Linear Technology ADI - Analog Devices vs. LLTC Linear Technology
Linear Tech (LLTC) Linear Tech (LLTC) Linear Tech (LLTC)
CUSIP: 535678106